Improved Gastrointestinal Tolerance and Patient Preference of Enteric-Coated Sulfasalazine Versus Uncoated Sulfasalazine Tablets in Patients with Rheumatoid Arthritis

Abstract

Off-label use of uncoated sulfasalazine tablets (TAB) by rheumatoid arthritis (RA) patients in the United States has resulted in poor gastrointestinal (GI) tolerance and compliance. Two studies have shown that treatment of inflammatory bowel disease with enteric-coated sulfasalazine ([EN] Azulfidine ENtabs) resulted in significantly less frequent and severe GI symptoms, compared with treatment with TAB. The current study was conducted to …